Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
November 2016
-
Media ReleaseInnovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originatorNo clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1] Innovative study design demonstrates switching between…
-
Media ReleaseNovartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine studySTRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus…
-
Media ReleaseNovartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancerFirst results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of…
-
Media ReleaseNew analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deathsEntresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1]…
-
Media ReleaseNovartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosisPriority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also…
-
Media ReleaseNovartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported painCosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high…
-
Media ReleaseNovartis improves ranking in 2016 Access to Medicine IndexNovartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income…
-
Media ReleaseNovartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancerPriority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…
October 2016
-
Media ReleaseNovartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology ProductBasel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "…
-
Media ReleaseNovartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbustersQ3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301…
-
Media ReleaseAlcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meetingAlcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle…
-
Media ReleaseNovartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II studyProgression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
Pagination
- ‹ Previous page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- …
- 88
- › Next page